In a small PhI trial, patients with newly diagnosed metastatic melanoma were given escalating doses of propranolol (which blocks the ability of stress hormones to interact with cells), as well as SOC (keytruda). The combination was safe and shows preliminary evidence of activity, demonstrating a higher response rate than expected with just keytruda alone https://clincancerres.aacrjournals.org/content/early/2020/10/30/1078-0432.CCR-20-2381